News

Celon Pharma S.A. voluntarily withdraws three batches of Salmex (500 µg + 50 µg)/ inhalation dose from the market. Under a decision of the Chief Pharmaceutical Inspector no. 4/WS/2018, issued at the request of Celon Pharma S.A., the MAH, one batch of Salmex (500 µg + 50 µg), used in treatment of asthma and COPDRead more »

In the German market, Salmex will be available under the trade name Salflutin. After completing the DCP registration procedure, the German drug registration authority will verify the national version of the information materials (including the leaflet, the medicine package) and will issue a final decision on marketing authorisation within the time limits set by theRead more »

We wish to inform you that a conference call with representatives of the Company’s Management Board will take place on 24 May 2018 (Thursday) at 10:30 am. The purpose of the meeting will be to summarise financial results for the first quarter of 2018 and to discuss the current situation in the Company. We inviteRead more »

Maciej Wieczorek, President of Celon Pharma S.A., will take part in this year’s Bioforum 2018, where he will hold a presentation on the novel approach to drug discovery and development process. Bioforum is one of the largest meetings of the biotechnology industry in Poland. This year it will be organised for the 17th time andRead more »

Over 28 million net revenues from sales of products, goods and materials; PLN 7.5 million of net profit – as compared to approx. PLN 5 million in the first quarter of 2017; A 7% quantitative growth of products sold and strengthening the leading position of most drugs from the portfolio in their respective therapeutic groups.Read more »

Celon Pharma representatives are taking part in the StarShip conference which takes place between 7 and 11 of May in Łódz. The purpose of the meeting is to inspire young people from all over Europe to take business and scientific initiatives in the field of Research and Development and in innovative branches of the economy.Read more »

During a poster session which will take place on 7 and 8 May 2018 at the Representatives of the American Psychiatric Association Annual Meeting CNS Research Group, representatives of the CNS Research Group will present two projects from the Company’s innovative portfolio. The sessions will be run by Mikołaj Matłoka – Leader of the CNSRead more »

107 million of sales income in 2017, enhancing the Company’s position on the Polish pharmaceutical market with an over 11% sale growth in terms of volume and4.3% in terms of value. 7 million of export sales with a significant growth potential covering new European countries in the coming months. Net profit for 2017 – 25.6Read more »

Celon Pharma S.A. has finalised the preclinical phase and has submitted an application to the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for the consent to commence the next stage of the trial, i.e. the clinical phase. Phase I of the CLP304110 trial is a multicentre trial carriedRead more »

President of the Company, Maciej Wieczorek, about Celon’s business plans and the perspectives of development of the Polish biotech industry in an interview given to Poland Healthcare & Life Sciences Review Pharmaceutical Executive Magazine. We encourage you to read the interview.